A set of doctors' perspectives on what clinicians see as emerging device technologies in cardiology, orthopedics, and neurology. This article is excerpted from Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, titled "Bringing Follow-on Funding to Heatlh Care."
By David Cassak and Stephen Levin
Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, was titled "Bringing Follow-on Funding...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.
